Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Search

TAG:

clia

With LDT Rule Vacated, Labs Await FDA Retort

CEO SUMMARY: In a major win for clinical laboratories, a federal judge vacated the FDA’s final rule on LDTs, writing in his decision that the agency overstepped its authority. For now, labs can develop and modify LDTs without FDA oversight, but future action in some form…

Read More



Why Labs Should Comply with FDA’s Final Rule on LDTs

CEO SUMMARY: Even as lawsuits challenging the Laboratory Developed Test (LDT rule) issued by the federal Food and Drug Administration (FDA) progress in federal court, clinical labs performing LDTs face an interesting decision. Should they invest the staff time and money to comply with the…

Read More



129,624 Genetic Tests in the United States

REGULATION OF LABORATORY DEVELOPED TESTS (LDTs) by the federal Food and Drug Administratio…

Read More



Physicians Tempted by Lure of In-Office Labs, Payers Balk

Read More



Assessing the Clinical Service & Revenue Issues of the LDT Rule

BARRING INTERVENTION BY FEDERAL COURTS OR THE U.S. Congress, clinical labo…

Read More



Language in Draft House Bill Directs FDA to Suspend LDT Rule

THERE IS AN INTERESTING NEW DEVELOPMENT associated with the regulation of laboratory deve…

Read More



Several Times, Feds Tried to ‘Redirect’ Lab Activities

CEO SUMMARY: Regulation of laboratory developed tests (LDTs) by the Food and Drug Administration (FDA) may turn out to be one of the most impactful federal laws or regulations ever promulgated, so far as it pertains to clinical laboratories.cThe Dark Report provides this historical look b…

Read More



Artificial Intelligence and Executive War College

By the time you read this our 29th annual Executive W…

Read More



FDA Issues Memo to Reclassify Many High Risk IVD Assays

WAS IT AN EXPECTED FLOOD OF APPLICATIONS TO REVIEW laboratory de…

Read More



Labs Should Prepare for Arrival of ‘Perfect Storm’

CEO SUMMARY: In the near future, clinical labs and pathology groups will need to address three major developments. One involves the FDA proposed LDT rule. A second is the adoption by payers of guidelines that require genetic test claims to have Z-Codes. The third centers around coming ref…

Read More



How Much Laboratory Business Intelligence Have You Missed?

Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!

Sign up for TDR Insider

Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.

;